CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Stock Information for Kandi Technologies Group Inc.
Loading
Please wait while we load your information from QuoteMedia.